UY34339A - 3-QUINASE PHOSPHYTIDYLINOSITOL INHIBITORS FOR CANCER TREATMENT - Google Patents

3-QUINASE PHOSPHYTIDYLINOSITOL INHIBITORS FOR CANCER TREATMENT

Info

Publication number
UY34339A
UY34339A UY0001034339A UY34339A UY34339A UY 34339 A UY34339 A UY 34339A UY 0001034339 A UY0001034339 A UY 0001034339A UY 34339 A UY34339 A UY 34339A UY 34339 A UY34339 A UY 34339A
Authority
UY
Uruguay
Prior art keywords
quinase
phosphytidylinositol
inhibitors
cancer treatment
página
Prior art date
Application number
UY0001034339A
Other languages
Spanish (es)
Inventor
Decillis Arthur
Lager Joanne
Emmons Gary Thomas
Ruiz Soto Rodrigo
Original Assignee
Exelixis Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Sanofi Sa filed Critical Exelixis Inc
Publication of UY34339A publication Critical patent/UY34339A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Escanear figura I página 3/26 y figura II página 4/26 SGDD
UY0001034339A 2011-09-14 2012-09-14 3-QUINASE PHOSPHYTIDYLINOSITOL INHIBITORS FOR CANCER TREATMENT UY34339A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US201161562670P 2011-11-22 2011-11-22

Publications (1)

Publication Number Publication Date
UY34339A true UY34339A (en) 2013-04-30

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034339A UY34339A (en) 2011-09-14 2012-09-14 3-QUINASE PHOSPHYTIDYLINOSITOL INHIBITORS FOR CANCER TREATMENT

Country Status (10)

Country Link
EP (1) EP2755654A1 (en)
KR (1) KR20140077911A (en)
AU (1) AU2012308414A1 (en)
BR (1) BR112014005858A2 (en)
CA (1) CA2848724A1 (en)
IL (1) IL231448A0 (en)
IN (1) IN2014CN02671A (en)
TW (1) TW201325592A (en)
UY (1) UY34339A (en)
WO (1) WO2013040337A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (en) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 Method for preparing Shakubaqu intermediate in continuous flow microreactor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
CN101395155A (en) 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 Pyridopyrimidinone inhibitors of pi3k alpha
JP5270353B2 (en) * 2005-10-07 2013-08-21 エクセリクシス， インク． Phosphatidylinositol 3-kinase inhibitor and method of use thereof
US8481001B2 (en) * 2007-04-11 2013-07-09 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of P13K-alpha for use in the treatment of cancer
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
IN2014CN02671A (en) 2015-07-03
IL231448A0 (en) 2014-04-30
WO2013040337A9 (en) 2014-04-03
WO2013040337A1 (en) 2013-03-21
BR112014005858A2 (en) 2017-06-13
AU2012308414A1 (en) 2014-05-01
TW201325592A (en) 2013-07-01
CA2848724A1 (en) 2013-03-21
EP2755654A1 (en) 2014-07-23
KR20140077911A (en) 2014-06-24

Similar Documents

Publication Publication Date Title
UY33925A (en) TRICYCLIC QUINASE INHIBITORS
UY34648A (en) AMIDAS AS PIM INHIBITORS
UY34550A (en) SUBSTITUTED BENCILPIRAZOLES
UY34145A (en) METALOENZYM INHIBITING COMPOUNDS
UY34146A (en) METALOENZYM INHIBITING COMPOUNDS
UY34374A (en) BENZILINDAZOLES REPLACED
UY34201A (en) AZAINDOL COMPOUNDS AND METHODS FOR HIV TREATMENT.
UY34045A (en) IMIDAZOPIRIDINE DERIVATIVES AS PI3K INHIBITORS
UY34156A (en) METALOENZYM INHIBITING COMPOUNDS
UY34657A (en) ? MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES ?.
UY4149Q (en) PET GOLOSINE
UY34472A (en) MODIFIED DERIVATIVES OF 4-PHENYL-PYRIDINE
UY34523A (en) BETULINA DERIVATIVES
GT201400133A (en) BROMODOMINIUM INHIBITORS
UY34051A (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
UY34039A (en) FUNGICIDE COMPOUNDS
UY34034A (en) TRIAZOLOPIRIDINS
UY34541A (en) ? DERIVATIVES OF DIHIDRO-BENZO-OXAZINA AND DIHIDRO-PIRIDO-OXAZINA ?.
UY34037A (en) NEW USEFUL COMPOUND FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.
UY34092A (en) NEW COMPOUNDS AS JAK INHIBITORS
UY33929A (en) TETRAS REPLACED CYCLHEXYL COMPOUNDS AS QUINASE INHIBITORS
UY33627A (en) COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES
UY34006A (en) IMIDAZOPIRIDAZINAS
EA201400178A1 (en) BREAST CANCER TREATMENT
UY34545A (en) NOVEDOSE DIHYDROPIRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR THE TREATMENT OF INFLAMMATORY DISORDERS.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020